BIAF
bioAffinity Technologies, Inc.NASDAQHealthcare$3.92+6.63%ClosedMarket Cap: $17.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.99
P/S
3.05
EV/EBITDA
-0.94
DCF Value
$-295.94
FCF Yield
-49.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
23.2%
Operating Margin
-171.6%
Net Margin
-242.0%
ROE
-385.2%
ROA
-136.0%
ROIC
-125.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.6M | 18.9% | $-3.1M | $-3.1M | $-1.82 | — |
| FY 2025 | $6.2M | 23.2% | $-10.6M | $-14.9M | $-8.66 | — |
| Q3 2025 | $1.4M | 27.0% | $-2.3M | $-5.1M | $-4.74 | — |
| Q2 2025 | $1.3M | 19.9% | $-2.5M | $-4.1M | $-5.07 | — |
| Q1 2025 | $1.9M | 26.2% | $-2.6M | $-2.7M | $-4.80 | — |
| Q4 2024 | $2.2M | 22.3% | $-2.9M | $-3.0M | $-6.00 | — |
| FY 2024 | $9.4M | 36.1% | $-9.0M | $-9.0M | $-22.50 | — |
| Q3 2024 | $2.4M | 38.7% | $-2.0M | $-2.0M | $-4.80 | — |
| Q2 2024 | $2.4M | 41.3% | $-2.1M | $-2.1M | $-5.70 | — |
| Q1 2024 | $2.4M | 34.6% | $-1.9M | $-2.0M | $-6.00 | — |
| Q4 2023 | $2.2M | 18.1% | $-2.3M | $-2.4M | $-7.80 | — |
| FY 2023 | $2.5M | 31.3% | $-8.0M | $-7.9M | $-27.30 | — |